Hitachi Chemical Advanced Therapeutics Solutions has two decades of experience utilizing the PCT global service platform, which is solely focused on cell therapy CDMO services at cGMP standards—including clinical manufacturing, commercial manufacturing, and manufacturing development.
Our Director of Research and Development, David Smith, joined Bio-Techne for their cell and gene therapy symposium, "Challenges of Analyzing ATMPs." The recording is now available for you to watch Dave discuss this topic from a CDMO perspective!
Watch the SymposiumWe are proud to announce an expansion of our relationship with bluebird bio! Along with apceth Biopharma, representing the Europe region of Hitachi Chemical’s global regenerative medicine business, we have entered into long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies.
Read Press ReleaseAt this time, our North American facilities are exempt from any government mandated closures. Please read the following article that details the precautions we are taking to keep our patients, clients, and employees safe during this time.
Read ArticleHitachi Chemical Advanced Therapeutics Solutions has completed a new cell and gene therapy manufacturing facility in Allendale, NJ. The new facility is expected to create up to 500 new jobs and help expand HCATS’ distribution area and capacity alike.
Learn More & Download ImagesOur Director of Research and Development, David Smith, joined Bio-Techne for their cell and gene therapy symposium, "Challenges of Analyzing ATMPs." The recording is now available for you to watch Dave discuss this topic from a CDMO perspective!
Watch the SymposiumWe are proud to announce an expansion of our relationship with bluebird bio! Along with apceth Biopharma, representing the Europe region of Hitachi Chemical’s global regenerative medicine business, we have entered into long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies.
Read Press ReleaseAt this time, our North American facilities are exempt from any government mandated closures. Please read the following article that details the precautions we are taking to keep our patients, clients, and employees safe during this time.
Read ArticleHitachi Chemical Advanced Therapeutics Solutions has completed a new cell and gene therapy manufacturing facility in Allendale, NJ. The new facility is expected to create up to 500 new jobs and help expand HCATS’ distribution area and capacity alike.
Learn More & Download ImagesDue to COVID-19, we are taking all necessary precautions to keep our employees safe. Guidance from the government in both New Jersey and California has confirmed that due to the nature of our business, our sites are exempt from business closure mandates at this time. Our North American sites will remain open and our critical operations are not impacted.
